Efficacy and Tolerability of OROS Hydromorphone in Strong Opioid-Naive Patients: An Open Label, Prospective Study / 대한내과학회지
Korean Journal of Medicine
; : 317-322, 2011.
Article
Dans Ko
| WPRIM
| ID: wpr-23779
Responsable en Bibliothèque :
WPRO
ABSTRACT
BACKGROUND/AIMS: OROS hydromorphone is a synthetic opioid agent. While clinical studies have tested its effectiveness at controlling cancer-associated pain in patients who have received other strong opioids, no clinical studies have tested its effectiveness at managing cancer pain in strong opioid-naive patients. We performed the present study to evaluate the efficacy and tolerability of OROS hydromorphone in strong opioid-naive cancer patients. METHODS: We administered OROS hydromorphone to patients who had not received strong opioids during the previous month. The starting dose was 8 mg/day. The dose was increased every 2 days in patients who experienced more than four episodes of breakthrough pain per day (more than four times in patients being treated with short-acting opioids). We evaluated the efficacy, safety and tolerability of ORS hydromorphone. We also evaluated patient satisfaction and investigators' global assessments. RESULTS: We enrolled 23 patients to the study. The decrease in the numeric rating scale (NRS) was 59%. NRS variation had decreased markedly during the previous 24 h. All patients achieved stable pain control. The side effects were similar to those of other strong opioids. In total, 26% of patients were very satisfied with the treatment and 47% satisfied, and 74% of the investigators deemed OROS hydromorphone to be very effective or effective at controlling cancer pain. CONCLUSIONS: OROS hydromorphone is an osmotically driven, controlled-release preparation that is very effective and safe when administered once daily to strong opioid-naive cancer patients.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Personnel de recherche
/
Études prospectives
/
Satisfaction des patients
/
Préparations à action retardée
/
Hydromorphone
/
Électrolytes
/
Douleur paroxystique
/
Analgésiques morphiniques
Type d'étude:
Observational_studies
/
Risk_factors_studies
Limites du sujet:
Humans
langue:
Ko
Texte intégral:
Korean Journal of Medicine
Année:
2011
Type:
Article